Skip to main content
. Author manuscript; available in PMC: 2020 May 15.
Published in final edited form as: Cancer Res. 2019 Oct 1;79(22):5826–5838. doi: 10.1158/0008-5472.CAN-19-1058

Figure 1. Pre-B-like cells accumulate in the spleens of mice with 4T1 cancer.

Figure 1.

Compared with follicular (FO) B cells (CD23+CD21+CD19+, R4) and MZ B cells (CD23−/LoCD21+CD19+), BM B-cell precursor-like CD25+ (R7) and CD25− (R6) IL7Rα+ CD21−CD23−CD19+ cells were increased in spleens of mice with and without 4T1 cancer, as shown in FACS dot plot (A and D), gene expression heat map (B and E, n=3–4) and transcription PCA analysis (C, n=3–6) of splenic B cells (B and C) and their FACS-sorted R7, R6, and R4 subsets (C and E) from BALB/c mice with 4T1.2 cancer, which were treated with control IgG (Ab, TB) or anti-CD20 Ab (TBA cells), or without cancer (NB). The PCA analysis (C) links TBA and R7 closer to BM B-cell precursors (pro-B and pre-B) than to other B cells (common lymphoid precursors, CLP; pre-pro-B; germinal center, GC; FOB; marginal zone, MZ; B1a; B1b; Transitional, Tr, newly formed, NF; and recirculating, reC) in the Immunological Genome Project. Expression of the BM B-cell precursor-specific genes (highlighted in Red, B and E) were confirmed with RT/PCR (F) and FACS analysis (G). The results were independently reproduced at least twice.